<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419977</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00023305</org_study_id>
    <nct_id>NCT01419977</nct_id>
  </id_info>
  <brief_title>Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo</brief_title>
  <official_title>Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease (SCD) is one of the most common inherited diseases worldwide and exhibits
      highest frequency in people of African descent. Patients with SCD currently have few
      treatment options, with hydroxyurea being the only medication approved to reduce the
      frequency of vaso-occlusive crisis (VOC) and prevent other SCD complications such as acute
      chest syndrome. Once patients develop VOC, hospitalizations aim to alleviate pain; no
      specific therapy is currently available to otherwise affect the course of the VOC. However,
      there has been increasing interest in the role of coagulation in the pathogenesis of SCD. The
      investigators hypothesize that low dose anticoagulant therapy, such as prophylactic dose
      low-molecular-weight heparin (LMWH), could be a novel way to ameliorate the vaso-occlusive
      process and thereby hasten the resolution of pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind prospective randomized placebo controlled study with an enrollment
      target of 100 patients. All subjects with SCD that meet inclusion criteria while inpatient,
      will be eligible for the study and randomized to receive prophylactic LMWH or placebo.
      Treatment with either LMWH (dalteparin 5000 IU subcutaneously daily) or placebo will occur
      for the initial 7 days of hospitalization. Randomization will occur within Investigational
      Drug Services, which will dispense and label medications to all patients. All patients will
      be followed throughout their hospitalization as well as in the outpatient clinic. The initial
      blood sample will be obtained within 36 hours of admission.

      Following randomization, blood will be drawn to perform: D-dimer, prothrombin fragment 1.2,
      thrombin-antithrombin complex, and Thrombin Generation Assay (TGA). Blood will be drawn as an
      inpatient (at admission, day 3, and day 5), as well as during a single outpatient follow-up
      visit two weeks post discharge. Patients with prolonged hospitalization will only have blood
      drawn on admission, day 3, and day 5, with a final blood draw as an outpatient (at least 14
      days after discharge). Treatment by prophylactic LMWH or placebo will occur for the initial 7
      days of hospitalization or until discharge.

      Clinical pain scores will be performed twice daily throughout for the initial 7 days of
      hospitalization of all patients. The primary pain assessment tool will be a 10-cm horizontal
      visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating
      the worst pain at the other. The VAS test will be administered by the same blinded study
      coordinator or PI throughout the study, using standardized instructions. Pain will also be
      assessed during the follow up outpatient visit (to confirm patient's pain has returned to
      their baseline).

      Patients will be recommended to follow up in outpatient clinic approximately 2-4 week
      following hospitalization. At this time, patients will be examined, have their clinical pain
      score determined, and have final blood draw for testing as detailed above. Should patients
      not return within 4 weeks, patient will be contacted by phone to determine their clinical
      status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>Day 1 and Day 3</time_frame>
    <description>Patients will have D-dimer,for samples drawn on Day 1 and Day 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Pain Scores</measure>
    <time_frame>Baseline to day 1</time_frame>
    <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Thrombin Generation Assay - Endogenous Thrombin Potential</measure>
    <time_frame>Day 1 and Day 3</time_frame>
    <description>Patients will have thrombin generation assay samples drawn on Day 1 and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Pain Scores</measure>
    <time_frame>Baseline to day 3</time_frame>
    <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Vaso-occlusive Crisis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalteparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5000 unites subcutaneously, Other Name: Fragmin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution, administered by nursing staff once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
    <arm_group_label>Dalteparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HgbSS or HgbS-beta0 thalassemia by previous hemoglobin electrophoresis,

          -  age greater than 18 years old, and

          -  admit diagnosis of vaso-occlusive crisis.

        Labs must be drawn within 36 hours of admission and randomization to treatment arm must
        occur during this time.

        Exclusion Criteria:

          -  End stage renal disease (creatinine &gt;3.0 mg/dL),

          -  use of antiplatelet or anticoagulation medication for an alternative indication,

          -  use of steroids or immunosuppressive medications,

          -  platelet count less than 100 X 109/L,

          -  history or development of heparin induced thrombocytopenia, packed red blood cell
             transfusion in the past one month, or

          -  recent hospitalization with discharge within the past 1 week.

        Patients with re-admissions will not be enrolled again and will have no further samples
        drawn.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nirmish Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <results_first_submitted>January 30, 2015</results_first_submitted>
  <results_first_submitted_qc>January 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2015</results_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>vaso-occlusive crisis</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 34 subjects were consented, 29 are received drug and had the day 1 blood draw. 2 subjects withdrew prior to receiving study drug. In addition, 2 subjects were discharged and 1 subject received a transfusion prior to the blood draw on day 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
        </group>
        <group group_id="P2">
          <title>Dalteparin</title>
          <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
        </group>
        <group group_id="B2">
          <title>Dalteparin</title>
          <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in D-dimer</title>
        <description>Patients will have D-dimer,for samples drawn on Day 1 and Day 3</description>
        <time_frame>Day 1 and Day 3</time_frame>
        <population>9 subjects were discharged prior to day 3 so the day 3 blood sample was not obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-dimer</title>
          <description>Patients will have D-dimer,for samples drawn on Day 1 and Day 3</description>
          <population>9 subjects were discharged prior to day 3 so the day 3 blood sample was not obtained.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478.8" spread="312.4"/>
                    <measurement group_id="O2" value="260.1" spread="200.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Clinical Pain Scores</title>
        <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with “0” corresponding to no pain at one end and “10” indicating the worst pain at the other.</description>
        <time_frame>Baseline to day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Pain Scores</title>
          <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with “0” corresponding to no pain at one end and “10” indicating the worst pain at the other.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.5"/>
                    <measurement group_id="O2" value="-1.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Thrombin Generation Assay - Endogenous Thrombin Potential</title>
        <description>Patients will have thrombin generation assay samples drawn on Day 1 and 3</description>
        <time_frame>Day 1 and Day 3</time_frame>
        <population>9 subjects were discharged prior to day 3 so the day 3 blood sample was not obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombin Generation Assay - Endogenous Thrombin Potential</title>
          <description>Patients will have thrombin generation assay samples drawn on Day 1 and 3</description>
          <population>9 subjects were discharged prior to day 3 so the day 3 blood sample was not obtained.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="34.5"/>
                    <measurement group_id="O2" value="-45.98" spread="47.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Clinical Pain Scores</title>
        <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with “0” corresponding to no pain at one end and “10” indicating the worst pain at the other.</description>
        <time_frame>Baseline to day 3</time_frame>
        <population>9 subjects were discharged prior to obtaining day 3 VAS score.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Pain Scores</title>
          <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with “0” corresponding to no pain at one end and “10” indicating the worst pain at the other.</description>
          <population>9 subjects were discharged prior to obtaining day 3 VAS score.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.2"/>
                    <measurement group_id="O2" value="-2.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Normal saline solution, administered by nursing staff once daily</description>
        </group>
        <group group_id="E2">
          <title>Dalteparin</title>
          <description>Dalteparin: Low molecular weight heparin (LMWH), 5000 units subcutaneously, administered by nursing staff once daily, Other Name: Fragmin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations to our pilot study include the small study sample size, which leads to difficulty in determining significant differences in the outcome measurements.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nirmish Shah, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-5350</phone>
      <email>nirmish.shah@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

